Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 40

Sort by

Sort Order Select

Journal Articles

Anti-HLA-I IgG Subclass Influences Antibody-Mediated Platelet Activation in the Context of Platelet Transfusion Refractoriness

Adèle Couvidou, Mathieu Wald, Catherine Angénieux, Juliana Pires Marafon, Marie-Joëlle Apithy, Luc-Matthieu Fornecker, Jerome Rollin, Blandine Maître

Blood (2024) 144 (Supplement 1): 2642.

https://doi.org/10.1182/blood-2024-197921

Published: 2024

Journal Articles

Ultrasensitive Circulating Tumor DNA MRD Status Predicts Treatment Failure & Complements PET/CT throughout Treatment for Early and Advanced Stage Classic Hodgkin Lymphoma

Jan Boegeholz, Cedric Rossi, Jordan S Goldstein, Stefan K. Alig, Andrea Garofalo, Mohammad Shahrokh Esfahani, Joseph G. Schroers-Martin, Chih Long Liu, Mari Olsen, Xiaoman Kang, Feng Tian, David Kurtz, Marc Andre, Luc-Matthieu Fornecker, Olivier Casasnovas, Maximilian Diehn, Herve Ghesquieres, Ash A. Alizadeh

Blood (2024) 144 (Supplement 1): 565.

https://doi.org/10.1182/blood-2024-201877

Published: 2024

Journal Articles

Distinct Molecular Aberrations of Classic Hodgkin Lymphoma in Older Adults Identified By Comprehensive Genomic Profiling

Blood (2024) 144 (Supplement 1): 853.

https://doi.org/10.1182/blood-2024-201644

Published: 2024

Journal Articles

Outcomes of Primary Mediastinal B-Cell Lymphoma Patients Treated with a PET-Guided Strategy in the Randomized Phase 3 Gained Study Conducted By Lysa

Blood (2024) 144 (Supplement 1): 575.

https://doi.org/10.1182/blood-2024-202446

Published: 2024

Journal Articles

Outcomes with Venetoclax-Based Treatment in Patients with Covalent Bruton Tyrosine Kinase Inhibitor (cBTKi)-Treated, Chemotherapy-Naïve Chronic Lymphocytic Leukemia (CLL): An International Retrospective Study

Blood (2024) 144 (Supplement 1): 1856.

https://doi.org/10.1182/blood-2024-198200

Published: 2024

Journal Articles

Minimal Residual Disease-Guided Combination of Ibrutinib and Venetoclax Compared to FCR in Untreated Patients with CLL of Intermediate Risk : Final Results of the Eradic Trial from the Filo Group

Blood (2024) 144 (Supplement 1): 584.

https://doi.org/10.1182/blood-2024-194593

Published: 2024

Journal Articles

Preemptive Therapy with Venetoclax for High-Risk Stage a CLL Patients: First Analysis of Prevene, a Phase II Trial of the Filo Group

Blood (2024) 144 (Supplement 1): 3256.

https://doi.org/10.1182/blood-2024-203081

Published: 2024

Journal Articles

Circulating Tumor DNA for Primary Mediastinal B-Cell Lymphoma Genotyping: A Prospective Multicenter Study

Vincent Camus, Pierre Sesques, Alessio Bruscaggin, Daphne Krzisch, Mathieu Viennot, Luc-Matthieu Fornecker, Morgane Cheminant, Sébastien Bailly, Franck Morschhauser, Pierre Feugier, Sylvain Choquet, Eric Durot, Sylvain Carras, Caroline Delette, Gandhi Damaj, Agathe Waultier-Rascalou, Pierre Lebreton, Katell Le Du, Krimo Bouabdallah, Roch Houot, Stéphane Vigouroux, Kamel Laribi, Laure Lebras, Lucie Oberic, Sandy Amorim, Simone Bocchetta, Pierre-Julien Viailly, Vinciane Rainville, Philippe Ruminy, Melody Caillot, Lodovico Terzi Di Bergamo, Georgia Alice Galimberti, Maria Cristina Pirosa, Matin Salehi, Gabriela Forestieri, Fanny Drieux, Elena-Liana Veresezan, Alexandra Traverse-Glehen, Marie Donzel, Emilie Leveque, Lucie Burel, Elodie Bohers, Marie-Delphine Lanic, Pascaline Etancelin, Stéphanie Becker, Pierre Decazes, David Tonnelet, Simon Draye-Carbonnier, Hervé Tilly, Fabrice Jardin, Davide Rossi

Blood (2024) 144 (Supplement 1): 4354.

https://doi.org/10.1182/blood-2024-202508

Published: 2024

Journal Articles

Outcomes of Patients with Hodgkin Lymphoma Receiving Brentuximab Vedotin (BV) As Maintenance Therapy after ASCT According to Previous Exposure to BV. a Retrospective Analysis of the EBMT Lymphoma Working Party in Collaboration with Geltamo, FIL, Lysarc, and Turkish Lymphoma Group

Blood (2024) 144 (Supplement 1): 1663.

https://doi.org/10.1182/blood-2024-205007

Published: 2024

Journal Articles

Tazemetostat in Combination with R-CHOP in Patients with High-Risk, Frontline Follicular Lymphoma (Epi-RCHOP): A Phase II Study from the Lysa

Blood (2023) 142 (Supplement 1): 297.

https://doi.org/10.1182/blood-2023-185057

Published: 2023

Journal Articles

Impact of Brentuximab Vedotin in Patients with Breast Implant-Associated Anaplastic Large Cell Lymphoma with Capsule Infiltration Requiring Chemotherapy

Blood (2023) 142 (Supplement 1): 4439.

https://doi.org/10.1182/blood-2023-188896

Published: 2023

Journal Articles

Synthetic Control Arm from Clinical Trials and Real-World Data from Lysa Group for Untreated Diffuse Large B Cell Lymphoma Patients Aged over 80 Years: A Bona Fide S trategy for Innovative Clinical Trials

Valentin Letailleur, Isabelle Chaillol, Fanny Cherblanc, Herve Ghesquieres, Frederic Peyrade, Fabrice Jardin, Stephanie Guidez, Fontanet Delices Bijou, Pierre Sesques, Cédric Rossi, Luc Matthieu Fornecker, Ludovic Fouillet, Sylvain Carras, Benoit Tessoulin

Blood (2023) 142 (Supplement 1): 72.

https://doi.org/10.1182/blood-2023-177708

Published: 2023

Journal Articles

Mixture Model to Predict the Cumulative Incidence of Relapses in Follicular Lymphoma : Need for Longer Follow-up or Alternative Outcomes

Blood (2023) 142 (Supplement 1): 7401.

https://doi.org/10.1182/blood-2023-189296

Published: 2023

Journal Articles

First Line Therapy Evaluation Using Propensity Score Approach in Newly Diagnosed Advanced Classical Hodgkin Lymphoma Patients from Prospective Real-World Realysa Cohort and Phase 3 AHL2011 Trial

Cedric Rossi, Amira Marouf, Benedicte Deau Fischer, Fanny Cherblanc, Emeline Cugnod, Loic Chartier, Luc Matthieu Fornecker, Marc Andre, Rene-Olivier Casasnovas, Herve Ghesquieres

Blood (2023) 142 (Supplement 1): 3056.

https://doi.org/10.1182/blood-2023-178154

Published: 2023

Journal Articles

Minimal Residual Disease-Guided Combination of Ibrutinib and Venetoclax Compared to FCR in Untreated Patients with CLL of Intermediate Risk : Interim Results of MRD Kinetics in the Eradic Trial from the Filo Group

Blood (2023) 142 (Supplement 1): 3268.

https://doi.org/10.1182/blood-2023-173341

Published: 2023

Journal Articles

Outcomes of CLL Patients Exposed to Venetoclax+/-R after Ibrutinib in France: The Resist Retrospective Study from the Filo-CLL Group

Loic Ysebaert, Emmanuelle Ferrant, Marie Sarah Dilhuydy, Anne-Sophie Michallet, Luca Inchiappa, Romain Guieze, Emmanuelle Tchernonog, Ana Cavillon, Marie Christine Bene, Luc-Matthieu Fornecker

Blood (2023) 142 (Supplement 1): 3273.

https://doi.org/10.1182/blood-2023-180696

Published: 2023

Journal Articles

Post-Transplant Lymphoproliferative Disorders (PTLD) in Real Life: Data from the French K-Virogref Registry on 525 Adult Patients

Blood (2023) 142 (Supplement 1): 443.

https://doi.org/10.1182/blood-2023-189133

Published: 2023

Journal Articles

Distinct Circulating Genomic Features of Classical Hodgkin Lymphoma of Older Adults

Cédric Rossi, Jan Boegeholz, Stefan K. Alig, Andrea Garofalo, Mohammad Shahrokh Esfahani, Joseph Schroers-Martin, Mari Olsen, Xiaoman Kang, David M. Kurtz, Takeshi Sugio, Mark P. Hamilton, Marc Andre, Rene-Olivier Casasnovas, Luc Matthieu Fornecker, Maximilian Diehn, Herve Ghesquieres, Ash A. Alizadeh

Blood (2023) 142 (Supplement 1): 4369.

https://doi.org/10.1182/blood-2023-178257

Published: 2023

Journal Articles

Early Autologous Hematopoietic Stem Cells (AHSC) Boost (HCB) to Overcome Immune Effector Cell-Associated Hematotoxicity (ICAHT) after CAR T-Cell Therapy for Lymphoma: A Single Center Experience

Safia Yousfi, Blandine Guffroy, Celestine Simand, Karin Bilger, Elise Toussaint, Mathieu Baldacini, Luc Matthieu Fornecker, Bruno Lioure

Blood (2023) 142 (Supplement 1): 6902.

https://doi.org/10.1182/blood-2023-182401

Published: 2023

Journal Articles

Genomic, Transcriptional, and Immunological Validation of Distinct Molecular Subtypes of Classic Hodgkin Lymphoma through Tissue-Based and Noninvasive Methods

Blood (2023) 142 (Supplement 1): 177.

https://doi.org/10.1182/blood-2023-186810

Published: 2023

NARROW

Anti-HLA-I IgG Subclass Influences Antibody-Mediated Platelet Activation in the Context of Platelet Transfusion Refractoriness

Ultrasensitive Circulating Tumor DNA MRD Status Predicts Treatment Failure & Complements PET/CT throughout Treatment for Early and Advanced Stage Classic Hodgkin Lymphoma

Distinct Molecular Aberrations of Classic Hodgkin Lymphoma in Older Adults Identified By Comprehensive Genomic Profiling

Outcomes of Primary Mediastinal B-Cell Lymphoma Patients Treated with a PET-Guided Strategy in the Randomized Phase 3 Gained Study Conducted By Lysa

Outcomes with Venetoclax-Based Treatment in Patients with Covalent Bruton Tyrosine Kinase Inhibitor (cBTKi)-Treated, Chemotherapy-Naïve Chronic Lymphocytic Leukemia (CLL): An International Retrospective Study

Minimal Residual Disease-Guided Combination of Ibrutinib and Venetoclax Compared to FCR in Untreated Patients with CLL of Intermediate Risk : Final Results of the Eradic Trial from the Filo Group

Preemptive Therapy with Venetoclax for High-Risk Stage a CLL Patients: First Analysis of Prevene, a Phase II Trial of the Filo Group

Circulating Tumor DNA for Primary Mediastinal B-Cell Lymphoma Genotyping: A Prospective Multicenter Study

Outcomes of Patients with Hodgkin Lymphoma Receiving Brentuximab Vedotin (BV) As Maintenance Therapy after ASCT According to Previous Exposure to BV. a Retrospective Analysis of the EBMT Lymphoma Working Party in Collaboration with Geltamo, FIL, Lysarc, and Turkish Lymphoma Group

Tazemetostat in Combination with R-CHOP in Patients with High-Risk, Frontline Follicular Lymphoma (Epi-RCHOP): A Phase II Study from the Lysa

Impact of Brentuximab Vedotin in Patients with Breast Implant-Associated Anaplastic Large Cell Lymphoma with Capsule Infiltration Requiring Chemotherapy

Synthetic Control Arm from Clinical Trials and Real-World Data from Lysa Group for Untreated Diffuse Large B Cell Lymphoma Patients Aged over 80 Years: A Bona Fide S trategy for Innovative Clinical Trials

Mixture Model to Predict the Cumulative Incidence of Relapses in Follicular Lymphoma : Need for Longer Follow-up or Alternative Outcomes

First Line Therapy Evaluation Using Propensity Score Approach in Newly Diagnosed Advanced Classical Hodgkin Lymphoma Patients from Prospective Real-World Realysa Cohort and Phase 3 AHL2011 Trial

Minimal Residual Disease-Guided Combination of Ibrutinib and Venetoclax Compared to FCR in Untreated Patients with CLL of Intermediate Risk : Interim Results of MRD Kinetics in the Eradic Trial from the Filo Group

Outcomes of CLL Patients Exposed to Venetoclax+/-R after Ibrutinib in France: The Resist Retrospective Study from the Filo-CLL Group

Post-Transplant Lymphoproliferative Disorders (PTLD) in Real Life: Data from the French K-Virogref Registry on 525 Adult Patients

Distinct Circulating Genomic Features of Classical Hodgkin Lymphoma of Older Adults

Early Autologous Hematopoietic Stem Cells (AHSC) Boost (HCB) to Overcome Immune Effector Cell-Associated Hematotoxicity (ICAHT) after CAR T-Cell Therapy for Lymphoma: A Single Center Experience

Genomic, Transcriptional, and Immunological Validation of Distinct Molecular Subtypes of Classic Hodgkin Lymphoma through Tissue-Based and Noninvasive Methods

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only